156 results about "Aqueous humor" patented technology

Described here are systems and methods for accessing Schlemm's canal and for delivering an ocular device or fluid composition therein. The ocular devices may maintain the patency of Schlemm's canal without substantially interfering with transmural fluid flow across the canal. The fluid composition may be a viscoelastic fluid that is delivered into the canal to facilitate drainage of aqueous humor by disrupting the canal and surrounding trabeculocanalicular tissues. Tools for disrupting these tissues and minimally invasive methods for treating medical conditions associated with elevated intraocular pressure, including glaucoma, are also described.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allows for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allows for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Described here are systems and methods for accessing Schlemm's canal and for delivering an ocular device or fluid composition therein. The ocular devices may maintain the patency of Schlemm's canal without substantially interfering with transmural fluid flow across the canal. The fluid composition may be a viscoelastic fluid that is delivered into the canal to facilitate drainage of aqueous humor by disrupting the canal and surrounding trabeculocanalicular tissues. Tools for disrupting these tissues and minimally invasive methods for treating medical conditions associated with elevated intraocular pressure, including glaucoma, are also described.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

An implant and method for regulating the intraocular pressure of an eye is described. The implant is disposed in Schlemm's canal of an eye through ab-externo or ab-interno canaloplasty. Once inserted, the implant monitors the intraocular pressure of an eye with a pressure sensor and provides regulated current to electrodes within the implant to perform electrolysis. Electrolysis causes a release of gas from the eye and a reduction in the volume of aqueous humor to decrease intraocular pressure. The degree of electrolysis and reduction of intraocular pressure is regulated by a platform that includes monitoring by a pressure sensor, safety controls, and remote access.

The embodiment of the invention discloses an operation evaluation system suitable for glaucoma. According to one specific embodiment, the system comprises a scanning device, a storage server, a main control chip and a display device, and the scanning device is used for scanning the eye structure of a user; the main control chip is configured to receive an eye image of a user and generate a three-dimensional eye model with a drainage valve; the main control chip is configured to obtain an initial aqueous humor flow finite element model, aqueous humor attribute information and aqueous humor inlet condition information from the storage server; the main control chip is configured to generate a finite element model to be solved according to the aqueous humor attribute information, the aqueous humor inlet condition information and the initial aqueous humor flow finite element model; the main control chip is configured to solve the finite element model to be solved; the main control chip is configured to generate operation evaluation information according to the simulation result information; and the main control chip is configured to control the display equipment to display the operation evaluation information. According to the embodiment, the safety of glaucoma treatment operation can be improved.

The invention belongs to the technical field of medicines, and discloses an application of a Necrosulfenamide (NSA) compound in preparation of a medicine for resisting glaucoma trabecular network fibrosis. The NSA can inhibit abnormal activation of necroptosis-related pathways and significantly down-regulate fibrosis key factors, so that the structure and function of trabecular meshwork tissues are improved, and the aqueous humor outflow capacity is recovered. It is found for the first time that NSA not only has a stable and lasting intraocular pressure lowering effect, but also can reduce retinal ganglion cell damage in an intraocular hypertension state, and has definite treatment and protection effects on non-acute glaucoma and intraocular hypertension. The regulation effect of NSA on trabecular meshwork fibrosis is not disclosed in the prior art, the research blank in the field is filled, and a new pharmacological target and a clinical application strategy are provided for prevention and treatment of glaucoma and related intraocular hypertension diseases.

Described here are systems and methods for accessing Schlemm's canal and for delivering an ocular device, tool, or fluid composition therein. The ocular devices may maintain the patency of Schlemm's canal without substantially interfering with transmural fluid flow across the canal. The fluid composition may be a viscoelastic fluid that is delivered into the canal to facilitate drainage of aqueous humor by disrupting the canal and surrounding trabeculocanalicular tissues. Some systems described here may be configured to cut or tear the trabecular meshwork with the body of an elongate member located within Schlemm's canal. Other tools for disrupting these tissues and minimally invasive methods for treating medical conditions associated with elevated intraocular pressure, including glaucoma, are also described.

Described herein are devices used to treat high intraocular pressure and glaucoma. An example device includes a plate comprising a first surface opposite a second surface. The first surface includes a series of fluid channels. The device also includes a first coating on the first surface and a second coating on the second surface. The device is configured to lower intraocular pressure by draining aqueous humor from an anterior chamber to subconjunctival space of a patient's eye.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

The invention relates to the technical field of intraocular pressure measurement, and discloses an artificial eyeball and an intraocular pressure monitoring simulation platform and method. The method comprises the following steps: controlling a water pressure regulator to regulate water pressure in a water injection pipeline and an artificial eyeball according to an intraocular pressure data model; a pressure sensor in the artificial eyeball senses and obtains a pressure electric signal in the artificial eyeball in real time; the pressure electric signal is transmitted to a transmitting coil through a signal wire, and the transmitting coil transmits the pressure electric signal to a receiving coil outside the artificial eyeball through mutual inductance; the receiving coil and the transmitting coil are in mutual inductance communication to receive and obtain a pressure electric signal, and the signal acquisition device acquires the pressure electric signal of the receiving coil to obtain an intraocular pressure measurement value; the actual intraocular pressure value is obtained by conducting signal collection on the water pressure sensor. By applying the system, the function of simulating the adjustable aqueous humor pressure and the blinking action can be achieved, high integration and intelligence are achieved, and accurate control and real-time monitoring of the change of the internal pressure of the simulated eyeball can be achieved.

Described here are systems and methods for accessing Schlemm's canal and for delivering an ocular device or fluid composition therein. The ocular devices may maintain the patency of Schlemm's canal without substantially interfering with transmural fluid flow across the canal. The fluid composition may be a viscoelastic fluid that is delivered into the canal to facilitate drainage of aqueous humor by disrupting the canal and surrounding trabeculocanalicular tissues. Tools for disrupting these tissues and minimally invasive methods for treating medical conditions associated with elevated intraocular pressure, including glaucoma, are also described.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

The invention discloses pranoprofen temperature-sensitive gel for treating xerophthalmia and a preparation method, the gel takes poloxamer 407 and poloxamer 188 as matrixes, the optimal ratio of the poloxamer 407 to the poloxamer 188 is 23.5%: 2%, and the ratio is optimized and determined by a central composite design-response surface method. During preparation, a blank gel solution is prepared firstly, and then auxiliary materials such as pranoprofen and the like are added for dissolution. The in-vitro release characteristic is good, the accumulated dissolution rate within 210 min exceeds 90%, and the zero-level pharmacokinetic process is achieved. An SD rat xerophthalmia model is established, and it is proved that the xerophthalmia treatment effect of the composition is better than that of eye drops. In eye tissue distribution and aqueous humor pharmacokinetic studies, higher target organ distribution characteristics are shown, the aqueous humor AUC0-t is 1.85 times that of eye drops, and the bioavailability is high. The invention further provides a gel preparation method, a drug effect evaluation method and a related research method, and a new effective dosage form and a new treatment thought are provided for xerophthalmia treatment.

The invention provides an ophthalmology minimally invasive drainage device with an expansion fixing function and a delivery system thereof, the ophthalmology minimally invasive drainage device comprises a drainage main body with a hollow cavity and an expansion fixing device, and the drainage main body comprises a near-end part and a far-end part far away from the near-end part; the expansion fixator is in a two-dimensional plane shape or a three-dimensional shape and is provided with a first end and a second end, the first end is connected with the near end part of the drainage main body, and the second end is connected with the far end part of the drainage main body; the near end part is one end close to the suprachoroidal space and has the length of 0.2-2.5 mm, and the far end part is one end close to the anterior chamber of the eye and has the length of 0.5-3.0 mm. According to the ophthalmology department minimally invasive drainage apparatus with the expansion and fixing functions, the drainage body with the hollow cavity is adopted, and the loading and implanting requirements can be met; after being released, the dilation fixer recovers to a preset shape, so that the dilation fixer can play a role in enhancing the intraocular fixing effect while playing a drainage role, ciliary body dissociation is formed, and then the effects of promoting aqueous humor absorption and inhibiting aqueous humor secretion are achieved.

The present invention relates to the field of medical device technology, and more specifically, to a split-type aqueous humor drainage device. The device comprises a puncture needle, a drainage tube, and a throttling structure. The puncture needle has a needle tip that passes through the lumen of the drainage tube, with its tip extending out of the tube to facilitate puncture. The throttling structure is provided separately from the drainage tube. During surgery, a medical professional places the drainage tube over the needle tip and performs a puncture at a predetermined location. The professional then inserts one end of the drainage tube into the predetermined location along the needle tip. The needle is then removed, causing aqueous humor to flow out of the drainage tube from the predetermined location. The throttling structure is then immediately connected to the drainage tube, and the throttling structure throttles the aqueous humor flowing out of the drainage tube to control the flow rate. Since the throttling structure is used alone, the medical professional does not need to control the aqueous humor flow rate, which is less susceptible to human factors and results in a relatively stable aqueous humor flow rate. Furthermore, the medical professional's operation is simplified, making the aqueous humor drainage procedure more efficient.

An implant device for an eye disease to be inserted into an eyeball may include: a tube having one end to be inserted into an anterior chamber of the eyeball, the tube comprising a hollow portion through which aqueous humor is drained; and a ripcord inserted into the hollow portion of the tube to control an amount of aqueous humor drainage through the tube. In the implant device, an inner diameter of the tube and a diameter of the ripcord are determined so that pressure formed in the anterior chamber of the eyeball when the tube is inserted into the anterior chamber of the eyeball is within a preset pressure range. The pressure formed in an anterior chamber to an optimal range through an appropriate combination of the tube and the ripcord inserted into the tube.

The utility model discloses an ophthalmology radiofrequency ablation training model which is used for assisting an ophthalmology radiofrequency ablation electrode used in cooperation with an ophthalmology radiofrequency ablation instrument in simulated puncture training on eyeballs, and the ophthalmology radiofrequency ablation electrode is provided with an electrode needle and an impedance detection unit electrically connected with the electrode needle. The ophthalmology radiofrequency ablation training model comprises a base and an eyeball model, wherein the eyeball model comprises a simulated sclera structure, a simulated ciliary body structure and simulated aqueous humor; the simulated sclera structure and the simulated ciliary body structure are made of conductive materials, the simulated sclera structure has a first impedance range, the simulated ciliary body structure has a second impedance range, and the simulated aqueous humor has a third impedance range; when the needle point of the electrode needle pierces into the simulated sclera structure, the simulated ciliary body structure and the simulated aqueous humor, the impedance detection unit can feed back an impedance value, and an operator can judge whether the piercing position and the piercing depth meet requirements or not according to the impedance value.

The invention provides an ophthalmology minimally invasive drainage device, and relates to the technical field of medical instruments. The device comprises a drainage tube, a dispersion tube and a release tube which are fixed into a whole, the longitudinal sections of the drainage tube, the dispersion tube and the release tube are flat, and a liquid inlet assembly used for liquid inlet is arranged at the left end of the drainage tube; the upper part of the drainage tube is provided with a fixing assembly for limiting an operation line; the dispersing pipe is fixedly connected with a fixing lug; the releasing pipe is in a circular arc shape, a pressure stabilizing film is arranged at the right end of the releasing pipe, and a pressure stabilizing opening is formed between the pressure stabilizing film and the releasing pipe. Through the arranged fixing assembly, the operation line can be limited, the stability of the drainage tube is guaranteed, the operation quality is improved, and operation complications are reduced; through the arrangement of the pressure stabilizing film and the pressure stabilizing opening, the size of the pressure stabilizing opening can be changed by utilizing the characteristic that the pressure stabilizing film deforms under pressure, the stable pressure of aqueous humor in the anterior chamber is ensured, and treatment of glaucoma is facilitated.

A plug for aqueous humor drainage tubes, an implantation device, and a removal device include a plug body, which is a conical structure. The bottom surface of the conical plug body is provided with a connecting protrusion extending outward, and the bottom surface of the plug body is provided with a magnetic connection structure. The magnetic connection structure is fixedly connected to the bottom surface of the plug body. The bottom surface of the plug body is also provided with an expansion layer structure, which is connected to the bottom surface of the plug body and covers the magnetic connection structure. The end of the magnetic connection structure extends outside the expansion layer structure. The present invention temporarily blocks the aqueous humor drainage tube of a glaucoma drainage implant to reduce the deposition of lens fragments, viscoelastics, inflammatory substances, etc. in the drainage tube during surgery, thereby reducing the intraocular pressure fluctuation of glaucoma patients after cataract surgery and avoiding the failure of glaucoma drainage implant surgery.

The invention provides extracellular vesicle proteins sPTPRG and Vincin of a biomarker for detecting retinal vein obstructive macular edema (RVO-ME) anti-VEGF treatment typing, the difference of the expression quantity of the extracellular vesicle proteins in aqueous humor of a patient is analyzed, the protein with remarkable expression difference is screened out, the protein can be used as the biomarker for RVO-ME treatment, and the application of the biomarker for detecting the anti-VEGF treatment typing of the retinal vein obstructive macular edema (RVO-ME) anti-VEGF treatment typing of the RVO-ME anti-VEGF treatment typing is facilitated. Important guidance is provided for personalized treatment of RVO-ME, and the method has a wide clinical application prospect.

The invention provides a gRNA, an AAV expression vector and a CRISPR-CasRx system for treating glaucoma, and particularly provides (a) a gene editing protein or an expression vector thereof, the gene editing protein comprises a VI type Cas protein; and (b) gRNA or an expression vector thereof, the gRNA is RNA for guiding the gene editing protein to be specifically combined with an aqueous humor outflow related gene and / or an aqueous humor generation related gene in an eye tissue, the aqueous humor outflow related gene comprises Rock1 and Rock2, and the aqueous humor generation related gene comprises Aqp1 and Adrb2. The gRNA designed aiming at exon regions of aqueous fluid outflow related genes (such as Rock1 and Rock2) and aqueous fluid generation related genes (such as Aqp1 and Adrb2) has the characteristics of relatively high editing efficiency and relatively low off-target rate, and the combination of the VI type Cas protein and the gRNA designed by the invention can effectively prevent and / or treat glaucoma or ocular hypertension.

The non-intrusive measuring system for the glucose concentration of the aqueous humor of the eyes comprises a linear polarization collimation light source which emits an incident polarized light beam along an advancing optical axis at a linear polarization starting angle, penetrates through a cornea, enters the aqueous humor and generates an emergent polarized light beam; the linear polarization starting angle of the incident polarized light beam is defined as a 45-degree rotation angle along the advancing direction of the advancing optical axis; the first polarization beam splitter is used for splitting the emergent polarized light beam into two emergent polarized light beam components with orthogonal polarization directions, and the two emergent polarized light beam components are respectively polarized at 0-degree and 90-degree rotation angles along respective advancing optical axis directions; the two light sensors are used for respectively measuring the light intensity of the two emergent polarized light beam components; an arithmetic processor for subtracting the light intensity to obtain a Schtort vector S1 component related to the amount of rotation of the polarization angle; and normalizing the S1 component by adding the light intensities of the emitted polarized light beam components as a standard value.